These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36602024)

  • 21. Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.
    Wadhwa A; Kutny MA; Xavier AC
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
    Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approach to the Treatment of Philadelphia Chromosome-Negative B-cell ALL in Older Adults: Is Age Becoming just a Number?
    Liu Y; Duong VH
    Curr Hematol Malig Rep; 2023 Jun; 18(3):68-74. PubMed ID: 36877337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comment on: Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
    Srinivasan S; Roy Moulik N; Dhamne C
    Pediatr Blood Cancer; 2023 Jan; 70(1):e29874. PubMed ID: 35735751
    [No Abstract]   [Full Text] [Related]  

  • 25. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.
    Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Topp MS; Fielding AK; Rambaldi A; Ritchie EK; Papayannidis C; Sterling LR; Benjamin J; Stein A
    J Clin Oncol; 2017 Jun; 35(16):1795-1802. PubMed ID: 28355115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Puzzolo MC; Radice G; Peragine N; de Propris MS; Mariglia P; Vignetti M; Vitale A; Bassan R; Annunziata M; Gaidano G; Rambaldi A; Chiaretti S; Guarini A; Foà R
    Blood; 2021 Dec; 138(22):2290-2293. PubMed ID: 34297829
    [No Abstract]   [Full Text] [Related]  

  • 28. Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
    El Chaer F; Holtzman NG; Sausville EA; Law JY; Lee ST; Duong VH; Baer MR; Koka R; Singh ZN; Hardy NM; Emadi A
    Acta Haematol; 2019; 141(2):107-110. PubMed ID: 30695783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
    Couturier MA; Thomas X; Raffoux E; Huguet F; Berthon C; Simand C; Gallego-Hernanz MP; Hicheri Y; Hunault Berger M; Saillard C; Leguay T; Loiseau C; Béné MC; Chevallier P
    Leuk Lymphoma; 2021 Mar; 62(3):620-629. PubMed ID: 33153370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction.
    Robinson AC; Marini BL; Pettit KM; Perissinotti AJ
    J Oncol Pharm Pract; 2020 Jan; 26(1):200-205. PubMed ID: 30760167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.
    Li Y; Moriyama T; Yoshimura S; Zhao X; Li Z; Yang X; Paietta E; Litzow MR; Konopleva M; Yu J; Inaba H; Ribeiro RC; Pui CH; Yang JJ
    Sci Adv; 2022 Dec; 8(50):eadd6403. PubMed ID: 36516256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Folan SA; Rexwinkle A; Autry J; Bryan JC
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S2-5. PubMed ID: 27521320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
    Ngo D; Otoukesh S; Stein AS; Forman S; Pullarkat V; Aldoss I
    Leuk Lymphoma; 2022 Nov; 63(11):2754-2756. PubMed ID: 35727173
    [No Abstract]   [Full Text] [Related]  

  • 36. Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia.
    Fuster JL; Bautista F; González B; Fernández JM; Rives S; Dapena JL;
    Clin Transl Oncol; 2021 Sep; 23(9):1963-1966. PubMed ID: 33742341
    [No Abstract]   [Full Text] [Related]  

  • 37. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Topp MS; Stelljes M; Zugmaier G; Barnette P; Heffner LT; Trippett T; Duell J; Bargou RC; Holland C; Benjamin JE; Klinger M; Litzow MR
    Leukemia; 2018 Feb; 32(2):562-565. PubMed ID: 28990581
    [No Abstract]   [Full Text] [Related]  

  • 38. Blinatumomab: first global approval.
    Sanford M
    Drugs; 2015 Feb; 75(3):321-7. PubMed ID: 25637301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.
    Mejstríková E; Hrusak O; Borowitz MJ; Whitlock JA; Brethon B; Trippett TM; Zugmaier G; Gore L; von Stackelberg A; Locatelli F
    Blood Cancer J; 2017 Dec; 7(12):659. PubMed ID: 29259173
    [No Abstract]   [Full Text] [Related]  

  • 40. Blinatumomab: A novel, bispecific, T-cell engaging antibody.
    May MB; Glode A
    Am J Health Syst Pharm; 2016 Jan; 73(1):e6-e13. PubMed ID: 26683683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.